Among the many hypothesized properties that researchers looking at this IGF-1 mimic may be aware of are:
- Muscle cell development and tissue repair
- Anti-cell aging potential
- Recovery time improvement
Studies suggest that this IGF-1 analog may be far stronger than the original, although there is little reliable data on the research. We have compiled an IGF-1 DES guide to help researchers with questions regarding the compound’s correct presentation.
Story Stages
IGF-1 DES Peptide: Mechanism of Action
Insulin-like growth factor 1 DES, or IGF-1 DES for short, is a splice variation of the hormone IGF-1. There is IGF-1 DES in the brain, and it has been theorized to encourage cell growth and specialization. There are 70 amino acids at the N-terminus of IGF-1, while there are only 67 in IGF-1 DES. This is due to the absence of the first three amino acids. Bones, muscles, and cartilage are believed to be the primary sites of IGF-1 binding after it has been mostly produced in the liver.
Natural IGF-1 is frequently discussed in conversations about growth hormone (hGH) because it has been theorized to regulate the effects of growth hormone in the organism. Proteins like IGF-1 DES and IGF-1 LR3, which are derivatives of IGF-1, have been suggested in several studies to promote muscle and bone growth and maintenance. Furthermore, it has been speculated to contribute to a strong metabolism and steady blood glucose levels.
The potential of IGF-1 to induce sulfate incorporation into rat cartilage led to its initial designation as a “sulfation factor” when it was first discovered in 1957 by Salmon and Daughaday. In clinical settings, IGF-1 has been examined in the context of muscular atrophy as a result of diseases such as HIV or in cases of hormonal imbalance.
Due to increased bioavailability caused by not attaching to insulin growth factor binding proteins, IGF-1 DES is believed to be potentially ten times more effective than IGF-1 in promoting hypertrophy. On the other hand, its half-life of around 30 minutes is much shorter than that of other IGF-1 derivatives.
IGF-1 DES Peptide Potential
Data from preclinical and clinical studies suggests that IGF-1 DES may have several impacts. Listed below are some possible actions of insulin-like growth factor-1 DES that researchers have considered.
IGF-1 DES Peptide and Muscle Cells
It has been hypothesized that insulin-like growth factor-1 (IGF-1 DES) and IGF-1 may promote skeletal muscle hypertrophy and activate glycolytic metabolism, two pathways the organism uses to source energy. The impact of IGF-1 DES on tissue proliferation is complicated and profound, but it is thought to help the organism activate systems that promote the flourishing of other growth factor hormones.
IGF-1 DES Peptide and Muscle Atrophy
Sarcopenia, or age-related skeletal muscle mass wasting, is considered more common in cases of dimished regeneration capacities. Researchers have speculated that IGF-1 DES may aid in preserving lean muscle mass. In addition to regulating muscle development, transforming growth factor-I (TGF-I) may promote myoblast proliferation and differentiation.
IGF-1 DES Peptide and Cognition
According to researchers, improved motor abilities, information processing speed, and fluid intelligence have been linked to high circulating IGF-1 levels. Indeed, research has indicated that greater levels of IGF-1 may be better able to ward against neuronal loss and cognitive decline, particularly in the development of Parkinson’s and Alzheimer’s diseases. In contrast, cognitive impairment has been associated with reduced IGF-1 signaling.
IGF-1 DES Peptide and Insulin Sensitivity
The hormones insulin and insulin-like growth factor-1 work together to steady blood sugar levels. In type 2 diabetic research models, studies have indicated that IGF-1 DES may lower blood sugar levels, enhance insulin sensitivity, and lower blood lipids. Less insulin is also needed due to this.
IGF-1 DES Peptide and Bone
Clinical trial data indicates that IGF-1 DES may have significant anabolic action, possibly enhancing bone production by acting directly on osteoblasts, protecting bone from damage. Higher levels of insulin-like growth factor-1 are linked to higher bone mineral density.
As skeletons develop, growth hormone and insulin-like growth factor 1 may play critical roles. Higher plasma IGF-1 DES concentrations were associated with better bone mineral density (BMD) and bone mineral content (BMC) in research study findings.
IGF-1 DES Peptide and Inflammation.
Because it may possibly lower endothelial cell oxidative stress, IGF-1 DES has been theorized to lessen inflammation and plaque in blood vessels. Researchers should note that lower levels of IGF-1 may be linked to cardiovascular disease, especially atherosclerotic cardiovascular disease (ASCVD).
Visit Core Peptides if you are a researcher interested in further studying the potential of IGF-1 DES peptide.
References
[i] Laron Z. The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab. 1999;84(12):4397-4404. doi:10.1210/jcem.84.12.6255
[ii] Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997;155(2):377-386. doi:10.1677/joe.0.1550377
[iii] Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996;28(10):1085-1087. doi:10.1016/1357-2725(96)00056-8
[iv] Remacle-Bonnet M, Garrouste F, el Atiq F, Roccabianca M, Marvaldi J, Pommier G. des-(1-3)- IGF-I, an insulin-like growth factor analog used to mimic a potential IGF-II autocrine loop, promotes the differentiation of human colon-carcinoma cells. Int J Cancer. 1992;52(6):910-917.
[v] Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle. 2011;1(1):4. Published 2011 Jan 24. doi:10.1186/2044-5040-1-4
[vi] Laumonier, Thomas & Menetrey, Jacques. (2016). Muscle injuries and strategies for improving their repair. Journal of Experimental Orthopaedics. 3. 10.1186/s40634-016-0051-7.
[vii] Antoine Salzmann, Sarah-Naomi James, Dylan M Williams, Marcus Richards, Dorina Cadar, Jonathan M Schott, William Coath, Carole H Sudre, Nishi Chaturvedi, Victoria Garfield, Investigating the Relationship Between IGF-I, IGF-II, and IGFBP-3 Concentrations and Later-Life Cognition and Brain Volume, The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 6, June 2021, Pages 1617–1629.
[viii] Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 DES axis in ageing and longevity. Nat Rev Endocrinol. 2013;9(6):366-376. doi:10.1038/nrendo.2013.67
